

NERVIANO MEDICAL SCIENCES

Nerviano Medical Sciences Announces Strategic acquisition of atamparib, a Phase II-ready PARP7 Inhibitor, from Ribon Therapeutics

NERVIANO, Italy and BOSTON, Mass., November 14, 2024 - Nerviano Medical Sciences S.r.l. (NMS) - a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Srl - a global leader in oncological innovation with a leading position in PARP1 inhibitor clinical development in brain cancer, is pleased to today announce the acquisition of atamparib, the first selective PARP7 inhibitor. This transaction highlights NMS's commitment to solidify its leadership in PARP biology and expanding its pipeline with transformative cancer therapies designed to meet significant unmet medical needs.

Strategic Enhancement of Oncology Portfolio: Atamparib is currently in Phase II with the potential to be first-in-class. This PARP7 inhibitor enriches NMS's diverse range of small molecules in the portfolio developed for various types of cancers. PARP7, a crucial target in oncology, is upregulated in response to cellular stress, promoting cancer cell survival. By targeting PARP7 in tumor cells, atamparib has been shown to inhibit cellular proliferation. It is an orally bioavailable small molecule with high potency on pre-clinical models, and a favorable safety and tolerability profile in PhI/II studies.

Leveraging Expertise in PARP Biology: NMS brings extensive knowledge in PARP biology, demonstrated through the development of NMS-293, an oral potent and selective PARP1 inhibitor with non-trapping effects and brain penetrant properties. NMS-293 has shown promising clinical activity in a Ph I/II study in combination with temozolomide in recurrent glioblastoma and astrocytoma patients. Building on this expertise and foundational research conducted by Ribon Therapeutics, NMS will advance the atamparib program into an innovative and effective therapy. This initiative reinforces NMS leadership in the development of PARP inhibitors.

Dr. Hugues Dolgos, CEO of Nerviano Medical Sciences, commented: *"We are excited about the addition of atamparib to our pipeline. NMS has been working on PARP7 for a long time, therefore, we believe that we are in a unique position to leverage our knowledge during the clinical development of atamparib. The very recent scientific evidence of the PARP7 biology is directing us to a different setting in which we believe we can demonstrate proof of concept in the clinical trials we plan to initiate in 2025"*.

About Nerviano Medical Sciences

[Nerviano Medical Sciences](https://www.nervianoms.com) S.r.l. (NMS Srl) is focuses on discovering and clinically developing small molecule New Chemical Entities (NCEs) for oncology, aiming to deliver first- and best-in-class personalized cancer treatments through innovative mechanisms and novel drug targets. Our pipeline, built from our validated kinase platform, includes projects from early preclinical to clinical stages, advanced both internally and in partnership.

NERVIANO MEDICAL SCIENCES

NMS Srl combines biotech agility with big pharma quality, guided by an experienced management team and a skilled staff with global expertise in research, drug discovery, and clinical development. Our capabilities are extended by NMS Group affiliates Accelera (AdMet) and NerPharMa (manufacturing), covering the entire drug development process.

A core strength lies in our renowned kinase inhibitor platform, featuring an extensive chemical library and IP coverage, which has led to successful out-licensing deals, including with encorafenib and entrectinib. Additionally, we are advancing a PARP-family-focused platform to discover NCEs targeting NAD-binding pockets, with potential expansion to other NAD-dependent enzymes. Our growing payload-linker platform further enhances our pipeline by enabling next-generation ADC production.

Collaborating globally with academic, clinical, and industry partners, we seek further strategic alliances to develop, commercialize, and expand our product portfolio while exploring in-licensing opportunities for promising clinical assets.

About NMS Group

[NMS Group](#), Italy's largest oncology-focused R&D company, employs over 400 individuals, with more than half in advanced research and manufacturing roles. Its kinase inhibitor and antibody-conjugate platforms drive innovation, establishing NMS as a global leader in personalized therapies. Notably, NMS discovered entrectinib, a targeted kinase inhibitor for NTRK1/2/3 and ROS1-dependent tumors, now commercialized globally through Roche.

The Group includes three subsidiaries: NMS S.r.l., focused on FIC/BIC cancer drug development with a dozen active projects; Accelera, a preclinical CRO; and NerPharMa, which manufactures APIs and drug products for clinical and commercial use.

Media Relations: sidney.dung@nmsgroup.it